Metoprolol succ er 50 mg tablet
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Metoprolol Succinate ER 50 mg Tablet: Pharmacokinetics, Efficacy, and Safety
Pharmacokinetics of Metoprolol Succinate ER 50 mg
Metoprolol succinate extended-release (ER) tablets are designed to provide a controlled release of the drug over a 24-hour period. Studies have shown that the pharmacokinetic (PK) profiles of brand name and generic formulations of metoprolol ER are generally similar, although there can be differences in the time to maximum concentration (Tmax). For instance, one study found that the Tmax for the brand was 6.1 hours, while it was 3.5 hours for one generic and 9.6 hours for another. Despite these differences, the overall exposure to the drug, measured by the area under the concentration-time curve (AUC) and maximum concentration (Cmax), was comparable across formulations.
Efficacy in Hypertension and Angina
Metoprolol succinate ER is effective in managing hypertension and angina pectoris. In a comparative study, both S-metoprolol ER (50 mg) and racemate metoprolol ER (100 mg) significantly reduced the number of angina attacks and improved blood pressure control in patients with chronic stable angina. The reduction in angina attacks was significant in both groups, with no significant difference between them, indicating that S-metoprolol at half the dose of racemate metoprolol is equally effective.
Bioequivalence and Formulation Variability
Bioequivalence studies have confirmed that different formulations of metoprolol succinate ER 50 mg tablets are bioequivalent under both fasting and fed conditions. This means that the test and reference formulations provide similar drug exposure, ensuring consistent therapeutic effects. However, formulation changes can impact drug release rates, which may lead to differences in pharmacokinetics. Despite these differences, the clinical impact on exercise-induced heart rate (EIHR) appears to be minimal, suggesting that EIHR may not be sensitive enough to detect minor pharmacokinetic variations.
Safety Profile
The safety profile of metoprolol succinate ER is well-established. Common adverse effects include fatigue, dizziness, and dyspnea, with no significant difference in the frequency or severity of adverse events between different formulations. In clinical practice, both S-metoprolol and racemate metoprolol are well-tolerated, with a similar incidence of adverse effects.
Conclusion
Metoprolol succinate ER 50 mg tablets are effective and safe for the management of hypertension and angina. While there can be differences in the pharmacokinetic profiles of various formulations, these do not translate into clinically significant differences in efficacy or safety. Both brand name and generic formulations are bioequivalent and provide consistent therapeutic benefits.
Sources and full results
Most relevant research papers on this topic